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Abstract
We studied somatomedin-C/insulinlike growth factor (Sm-C/
IGF-I) binding to human fibroblasts in both adherent monolayers
and in suspension cultures. The addition of Sm-C/IGF-I in con-
centrations between 0.5 and 10 ng/ml to monolayers cultures
resulted in a paradoxical increase in `~I-Sm-C/IGF-I binding
and concentrations between 25 and 300 ng/ml were required to
displace the labeled peptide. The addition of unlabeled insulin
resulted in no displacement of labeled Sm-C/IGF-I from the
adherent cells. When fibroblast suspensions were used Sm-C/
IGF-I concentrations between 1 and 10 ng/ml caused displace-
ment, the paradoxical increase in 1I-Sm-C/IGF-I binding was
not detected, and insulin displaced 60% of the labeled peptide.
Affinity cross-linking to fibroblast monolayers revealed a 43,000-
mol wt i1.I-Sm-C-binding-protein complex that was not detected
after cross-linking to suspended cells.
The 43,000-mol wt complex was not detected after cross-
linking to smooth muscle cell monolayers, and binding studies
showed that i`SI-Sm-C/IGF-I was displaced >90% by Sm-C/
IGF-I using concentrations between 0.5 and 10 ng/ml. Because
fibroblast-conditioned medium contains the 43,000-mol wt com-
plex, smooth muscle cells were incubated with conditioned me-
dium for 24 h prior to initiation of the binding studies. '25I-Sm-
C/IGF-I-binding increased 1.6-fold compared to control cultures
and after cross-linking the 43,000-mol wt complex could be de-
tected on the smooth muscle cell surface. Human fibroblast
monolayers secrete a protein that binds i`SI-Sm4/IGF-I which
can be transferred to the smooth muscle cell surface and alters
I-Sm-C/IGF-I binding.
Introduction
Cultured human skin fibroblasts have been studied extensively
as a model to determine the effects of somatomedins on cell
growth and DNA synthesis (1, 2). Several investigators have an-
alyzed the characteristics of binding of '251I-somatomedin-C/in-
sulinlike growth factor I (Sm-C/IGF-I)' to cultured fibroblasts
and compared its binding properties with its cell growth-stim-
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1. Abbreviations used in this paper: DME, Dulbecco's modified Eagle's
medium; DSS, disuccinimidyl suberate; DTT, dithiothreitol; EGF, epi-
dermal growth factor, FCS, fetal calf serum; MEM, Eagle's minimum
essential medium; PAGE, polyacrylamide gel electrophoresis; Sm-C/IGF-
I, somatomedin-C/insulinlike growth factor-I.
ulating properties (3, 4). To perform binding studies, suspended
cell systems have been commonly used (3-5). Suspended fibro-
blasts have been shown to possess two types of somatomedin
receptors (6, 7). The type I receptor has two subunits, Mr
= 135,000 (alpha) and 95,000 (beta), and binds Sm-C/IGF-I
with a higher affinity than IGF-II and both with a greater affin-
ity than for insulin; whereas the type II receptor has an Mr
= 260,000, binds IGF-II preferentially, and does not bind insulin.
In order to determine the effects ofsomatomedins onDNA syn-
thesis, however, adherent monolayer cultures must be used be-
cause fibroblasts in suspension do not undergo DNA synthesis
and division. Exposure to trypsinization and removal ofthe cells
to create suspended cell preparations have been shown to alter
the binding of peptide growth factors to cell surface receptors
(8) and various conditions such as treatment at 4°C and the use
ofchelating agents have been adopted in order to minimize these
alterations. It has been reported that human fibroblast mono-
layers possess specific Sm-C/IGF-I receptors, that bound Sm-C/
IGF-I is fully dissociable, that displacement of bound '251-Sm-
C/IGF-I occurs at concentrations of unlabeled Sm-C/IGF-I be-
tween 1 and 100 ng/ml (9, 10), and that insulin when added at
a concentration of 10 ,ug/ml displaces >60% of '25I-Sm-C/IGF-
I from the monolayers. In contrast other investigators have re-
ported that although there are type I receptors present in fibro-
blast monolayers, binding to the type I receptor may represent
only a small portion of the total '251-Sm-C/IGF-I that is
bound (1 1).
In attempting to perform similar binding studies we were
not able to effectively displace labeled Sm-C/IGF-I from fibro-
blast monolayers using concentrations in the range of 1.0-10
ng/ml, and the addition of insulin resulted in no displacement.
Because monolayer cultures are required to demonstrate Sm-
C/IGF-I stimulation of replication, we undertook studies using
monolayer cultures to define the factors responsible for our in-
ability to displace the labeled peptide effectively and to test the
hypothesis that an additional cell surface protein was present
that could bind Sm-C/IGF-I but not insulin.
Methods
Cell culture techniques. Human fibroblasts were purchased from the Hu-
man Mutant Genetic Cell Repository (Camden, NJ) or obtained from
foreskins ofnewborn donors. Fibroblasts that were purchased were dermal
in origin and were obtained from donors of varying ages. These include
GM-10, 12 wk fetal; GM-4392, 16 wk fetal; GM-4525, 17 wk fetal; GM-
1437, newborn; GM-498, 3 yr-, GM-1362, 14 yr, GM-6291, 90 yr-, GM-
731, 96 yr. All cultures were plated in plastic petri dishes (Falcon Labware,
Oxnard, CA) using Eagle's minimum essential medium (MEM) supple-
mented with penicillin 100 U/ml, streptomycin 100 Ag/ml, purchased
from Grand Island Biological Company (Gibco, Grand Island, NY) and
10% bovine serum (Colorado Serum Co., Denver, CO). Fetal calfserum
(FCS), used in some experiments, was purchased from two sources;
HyClone Laboratories (Denver, CO; lot 110454) and Gibco (lot 36K824).
Cells were routinely cultured in 10-cm dishes (Falcon 3001) in MEM
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containing 10% calf serum and were incubated at 370C in a humidified
atmosphere containing 5% CO2 and 95% air. The medium was changed
every third day and the cells were harvested by trypsinization (trypsin
0.1%, EDTA 0.03%, Gibco) and replated approximately once every 10
d using the split ratio of 1:4. Both stock and test cultures were examined
at monthly intervals for Mycoplasma pneumoniae and were found to be
uncontaminated. For studies of 251I-Sm-C/IGF-I binding stock cultures
were subcultured into 24-well plates (Falcon 3004, 16-mm diam) using
a plating density of 10,000 cells/cm2 except where variations in plating
density were required to achieve differences in final cell density. Cells
were cultured for 3 d in MEM supplemented with 10% FCS then the
medium was changed and the incubation continued for an additional 3
d. Cell number was determined in triplicate wells using a Coulter Counter
(Coulter Electronics, Inc., Hialeah, FL) on the day that the binding ex-
periment was performed.
Determination of'25I-Sm-C/IGF-I binding to monolayer fibroblast
cultures. Quiescent monolayers were washed three times with phosphate-
buffered saline (PBS) and then the cultures were exposed to binding
medium containing MEM plus Hepes 20 mM and 0.1% bovine serum
albumin (BSA) (pH 7.4). '25I-Sm-C/IGF-I (prepared as described below)
was added at a concentration of 80,000 cpm/well in a final incubation
volume of 0.25 ml. After a 2-h incubation at 80C (there was no further
increase in binding during a 3- or 4-h incubation) the medium was as-
pirated, the cells were washed three times with cold PBS, and then sol-
ubilized using 0.3 N NaOH for I h at 220C. Cell lysates were transferred
to plastic tubes and '25I-Sm-C/IGF-I that was cell associated was deter-
mined in a Beckman gamma spectrometer (Beckman Instruments, Inc.,
Palo Alto, CA). Nonspecific binding was determined by subtracting the
radioactivity bound in the presence ofan excess (1.0 ytg/ml) ofunlabeled
Sm-C/IGF-I that had been partially purified by a previously described
method ( 12). Total radioactivity bound was consistently in the range of
5-9% and nonspecific binding was consistently < 15% ofthe total bound
or the experiment was discarded. In all experiments in which competition
curves were generated, unlabeled Sm-C/IGF-I or insulin was added at
increasing concentrations varying between Sm-C/IGF-I 0.1 and 300 ng/
ml or insulin between 1.0 and 10.0 ;ig/ml.
Suspendedfibroblast cultures. Fibroblast cell suspensions to be used
for binding studies were prepared as follows: confluent monolayers were
treated with 0.1% trypsin in 0.03% EDTA for I min at 24°C and the
reaction was stopped by addition ofMEM plus 10% FCS. The cells were
pelleted then resuspended in 0.25 ml of binding buffer and added to 12
X 75-mm polystyrene tubes (1-1.5 X 106 cells/tube). '25I-Sm-C/IGF-I
( 120,000 cpm) was added to each tube. Tubes were incubated for 2 h at
8°C with agitation every 15 min then washed once with 0.5 ml of PBS
and once with 1.0 ml of PBS. After centrifugation the cell pellet was
counted.
Preparation ofgrowthfactors. Pure preparations ofSm-C/IGF-I were
used in all experiments except to determine nonspecific binding. The
purification procedure and criteria for purity have been previously pub-
lished (13). Purified Sm-C/IGF-I was iodinated by a modified chloramine-
T method (14) to a specific activity of 300 sCi/;g. After iodination the
peptide was further purified by affinity chromatography using a Sephar-
ose-linked IgG Sm-C/IGF-I antibody. Impure Sm-C/IGF-I that was used
to determined nonspecific binding was purified by acid extraction of
acromegalic plasma followed by SP-Sephadex and G-50 Sephadex gel
filtration chromatography as previously published (12). Porcine (PJ-5682)
and human insulin were a gift from the Eli Lilly Co. (Indianapolis, IN).
IGF-II was purified by a previously described method and purity was
confirmed by amino acid sequencing (15).
Preparation ofconditioned medium. Quiescent fibroblast or smooth
muscle cell monolayers that had been grown to confluency on 10-cm
plates were washed three times with PBS and exposed to serum-free
MEM for 72 h at 37°C. The conditioned medium was removed, cen-
trifuged at 2,000 g for 15 min to remove cellular debris, and stored at
-20°C until use (usually within 2 wk).
Determination ofSm-C/IGF-I binding to smooth muscle cultures.
Smooth muscle cells were isolated from the aortas of 3-wk-old piglets
by a previously published method (16). Stock cultures were maintained
in 10-cm dishes (Falcon 3001) in Dulbecco's modified Eagle's medium
(DME) supplemented with 109% FCS (Gibco), glutamine 10mM (Gibco),
penicillin 100 U/ml, and streptomycin 100 ,ug/ml (Gibco). Media was
changed every third day until growth was confluent (1 1 d), then the cells
were removed by exposure to 0.1% trypsin, 0.03% EDTA (Gibco), and
replated between cell densities of 10,000- 12,000 cells/cm2. To determine
Sm-C/IGF-I binding to porcine aortic smooth muscle cells these cells
were plated in 24-well 16-mm dishes (Falcon 3004) at a density of6,000
cells/cm2 in DME containing 10% FCS. After 6 d of incubation cells
were washed extensively with PBS and then exposed to serum-free me-
dium containing a 50% concentration ofconditioned medium from either
human fibroblast cultures or porcine aortic smooth muscle cells. After
a 14-48-h incubation in DME containing the conditioned medium, the
confluent monolayers were again washed extensively and '`I-Sm-C/IGF-
I (80,000 cpm/well) was added to 0.25 ml ofDME supplemented with
20 mM Hepes, 0.1% BSA, pH 7.4, and the incubation continued for 2
h at 8VC. Specific binding of cell-associated '25I-Sm-C/IGF-I was deter-
mined as described for the fibroblast cultures.
Affinity cross-linking studies. Affinity labeling was performed ac-
cording to a modification ofmethods described by Adams et al. (17) and
Wilkins and D'Ercole (18). Briefly, the conditioned media was incubated
with 251I-Sm-C/IGF-I at room temperature for 10 min in Hepes binding
buffer with BSA 1%, pH 7.4, with or without varying concentrations of
unlabeled Sm-C/IGF-I and insulin. The cross-linking agent, disuccinim-
idyl suberate (DSS; Pierce Chemical Co., Rockford, IL) was then added
in a final concentration of 0.5 mM and the samples incubated for 10
min at 220C. The reaction was stopped by the addition of 50 mM Tris
and the samples hydrolyzed by boiling for 5 min. The proteins were
then separated by 10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE).
For studies on the monolayer cultures the fibroblasts or smooth mus-
cle cells were grown to confluency in 35-mm dishes (Falcon), washed
three times with Hepes binding buffer containing BSA 1%, pH 8.0, and
incubated with 25I-Sm-C/IGF-I in the same buffer at 4°C for 2 h with
or without varying concentrations of unlabeled Sm-C/IGF-I, insulin or
the anti-type I-receptor monoclonal antibody. The hybridoma cell line
producing the monoclonal antibody to the type I receptor, designated
alpha-IR3, was a gift ofDr. Steven Jacobs (Burroughs Wellcome, Research
Triangle Park, NC). This antibody, which is directed at the type I Sm-
C/IGF-I receptor (19), was amplified in ascites fluid and purified by
sequential precipitation in 18% and 15% sodium sulfate. In a preliminary
study of the time of incubation (2-18 h), the longer incubations resulted
in a slight increase in intensity oflabeled bands seen on autoradiography,
but in no differences in the protein species that bound to 1251-Sm-C/
IGF-I. The monolayers were then washed twice with cold Hepes buffer
without BSA, pH 7.4, and DSS was added in a final concentration of
0.1 mM in 1.0 ml ofthe same buffer. After a 10-min incubation at room
temperature, the reaction was quenched with 3 vol 10 mM Tris, pH 7.0,
and 1 mM EDTA. After 5 min, the Tris-EDTA was aspirated and the
cells were solubilized in 0.1 ml of 50 mM Tris, 2% SDS with or without
100 mM dithiothreitol (DTT). The cell lysate was transferred to a 1.5-
ml microfuge tube and boiled for 5 min, and the proteins were separated
on 3-14% gradient SDS-PAGE (20). The gels were fixed with 10% acetic
acid and 30% methanol, washed, dried, and then exposed to Kodak
X-0 mat film (Eastman Kodak Co., Rochester, NY). The autoradiograms
were then developed by standard techniques. The molecular weights of
the standards used were: myosin 200,000; phosphorylase B 97,400, BSA
68,000; ovalbumin 43,000; alpha-chymotrypsinogen 25,700; beta-lac-
toglobulin 18,400; lysozyme 14,300 (Bethesda Research Laboratories,
Gaithersburg, MD).
Results
Between 5% and 9% of the radiolabeled Sm-C/IGF-I bound to
the fibroblast monolayers. When increasing concentrations of
unlabeled Sm-C/IGF-I (1-20 ng/ml) were added, however, 125I-
Sm-C/IGF-I binding increased 40-65% over basal and decreased
only when concentrations were increased to between 25 and 300
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ng/ml (Fig. 1). In contrast, when 1251I-Sm-C/IGF-I binding was
determined using suspension cultures, low concentrations ofSm-
C/IGF-I (0.5-10 ng/ml) displaced significant amounts of the
labeled peptide (Fig. 1). To determine whether this phenomenon
was limited to one fibroblast strain, monolayer cultures prepared
from eight other fibroblast strains were analyzed for the capacity
of Sm-C/IGF-I to displace labeled Sm-C/IGF-I. In all the cell
lines tested, there was a significant increase in '251-Sm-C/IGF-I
binding at low concentrations ( 1-10 ng/ml) and no lines showed
>29% displacement at the 50 ng/ml concentration (Table I).
Because high concentrations of unlabeled insulin have been
shown to compete effectively for binding of 125I-Sm-C/IGF-I to
type I receptors, increasing concentrations of unlabeled insulin
were incubated with '251I-Sm-C/IGF-I to determine the capacity
of this peptide to displace bound '25I-Sm-C/IGF-I from the ad-
herent monolayers and from cells in suspension. Unlabeled in-
sulin displaced 60% ofthe labeled material from suspended cells
(Fig. 2) but had no effect on binding of 1251I-Sm-C/IGF-I to the
adherent monolayers. Again when eight other cell lines were
tested unlabeled insulin was incapable of displacing 1251-Sm-C/
IGF-I from adherent cultures (Table I). It appears, therefore,
that in monolayer culture most ofthe 1251I-Sm-C/IGF-I is binding
to a site that does not bind insulin.
Alterations in the experimental conditions prior to perform-
ing the binding experiments on monolayers did not change the
sensitivity of fibroblast '251I-Sm-C/IGF-I binding to competition
by unlabeled Sm-C/IGF-I. Specifically, when monolayer cultures









Figure 1. Binding of Sm-C/IGF-I to human fibroblast monolayers and
cell suspensions. Human fibroblast monolayers (o) were grown to con-
fluency (85,000 cells/well) as described in methods. After extensive
washing with PBS, 0.25 ml ofDME containing 25 mM Hepes, 0.1%
BSA, pH 7.4 was added. '25I-Sm-C/IGF-I (80,000 cpm/well) was
added and the incubation was continued for 2 h at 8°C. The mono-
layers were then washed three times with PBS, solubilized in 0.3 N
NaOH, and the cell-associated radioactivity was determined. Cell sus-
pensions (.) were prepared by exposing monolayer cultures to trypsin
0.1%, EDTA 0.03% for 1 min, and after transfer of 1.5 X 106 cells/
tube in 0.25 ml of buffer, were incubated with 120,000 cpm '25I-Sm-
C/IGF-I for 2 h at 8°C. After centrifugation, the cell associated '25I-
Sm-C/IGF-I was quantitated. Increasing concentrations of unlabeled
Sm-C/IGF-I (0-300 ng/ml) were added simultaneously with '25I-Sm-
C/IGF-I to triplicate cultures and each point is the mean value.
Table I. Binding ofSm-C/IGF by Several Fibroblast Strains
% of control bound*
Sm-C/IGF added
Insulin added
Cell designation Donor age 34 ng/ml 50 ng/ml 10 pg/ml
GM-10 12 wk (fetal) 133±7 94±6 91±9
4392 12 wk (fetal) 140±12 104±5 102±4
1523 3 d 128±11 87±9 94±11
1437 3 d 117±6 91±11 94±9
498 3 yr 112±11 76±7 95±2
1362 14 yr 130±2 93±4 98±6
6291 90 yr 114±10 71±9 99±13
731 96 yr 115±8 82±10 87±10
* Control binding is defined as the amount of '251-Sm-C/IGF-I bound
in the absence of any unlabeled SM-C/IGF-I.
or when the interval since the last media change prior to per-
forming the binding experiment was varied from 1 to 5 d, Sm-
C/IGF-I binding was not altered. If the fibroblast monolayers
were exposed to serum-free media for 48 h with two media
changes prior to initiation of the experiment, however, the par-
adoxical increase in Sm-C/IGF-I binding was eliminated but the
cultures were still relatively insensitive to competition by un-
labeled Sm-C/IGF-I.
To investigate the possibility that in monolayer cultures Sm-
C/IGF-I was binding to a site other than the type I receptor, a
specific type I receptor monoclonal antibody (alpha-IR3) was
added at increasing concentrations to both suspended and
monolayer cultures and coincubated with '251I-Sm-C/IGF-I. This
antibody caused no displacement of radiolabeled Sm-C/IGF-I
from the monolayers cultures, even when concentrations as high
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Figure 2. Competition between '25Sm-C/IGF-I and insulin for binding
to fibroblast monolayers and suspension cultures. Both fibroblast
monolayers (o; density = 88,000 cells/well) and suspension cultures
(.) were prepared as described in Fig. 1. After addition of increasing
concentrations of insulin (0-10 ,g/ml) the incubations were carried
out and cell-associated 1251I-Sm-C/IGF-I was determined as described
in Fig. 1.
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Figure 3. Competition between type I receptor antibody (alpha-IR3)
and '25I-Sm-C/IGF-I for binding to fibroblast monolayers (77,000
cells/well) and suspension cultures. Fibroblast monolayers (o) and sus-
pension cultures (e) were prepared as described previously and were
exposed to '25I-Sm-C/IGF-I and increasing concentrations of antibody,
(0.1-100 nM) then incubated as in Fig. 1. Cell-associated radioactivity
after the incubation was determined as in Fig. 1. Each point represents



















IGF-I in suspension cultures (Fig. 3). This finding suggests that
the '25I-Sm-C/IGF-I is bound to a site other than type I receptor
(i.e., a receptor that does not bind insulin such as the type II
receptor), and that the type I receptor binding represents only
a very low percentage of the total binding observed.
To determine the characteristics of the '25I-Sm-C/IGF-I
binding moiety, affinity cross-linking studies were performed.
After cross-linking '25I-Sm-C/IGF-I-binding complexes from
monolayer cultures were subjected to SDS-PAGE under reducing
conditions and autoradiographed. Two major bands (Fig. 4) were
observed: a 135,000-mol wt band, characteristic of the alpha-
subunit ofthe type I receptor, and a more intensely labeled band
at 43,000. A less intense band of -260,000 mol wt was also
observed. The 260,000-, 135,000-, and 43,000-mol wt bands
were either reduced in intensity or obliterated in the presence
of 50 ng/ml unlabeled Sm-C/IGF-I. High concentrations of in-
sulin (20 Ag/ml) partially displaced labeled Sm-C/IGF-I from
the 135,000-mol wt band and the 260,000-mol wt band, but not
from the 43,000-mol wt band (Fig. 4). Similarly alpha-IR3 in-
hibited labeling ofthe 135,000-mol wt subunit and the 260,000-
mol wt band. In the presence oflow concentrations ofunlabeled
Sm-C/IGF-I, however, the intensity of labeling of both the
135,000- and 43,000-mol wt bands was apparently increased
(Fig. 5). To exclude the possibility that the binding protein in
the 43,000-mol wt complex was associated with the culture dish
or cellular matrix and not the cell surface, the matrix was ex-
tracted after cell removal with Triton x-100 and the counts per
minute associated with the plastic surface also quantitated. Less
than 8% of the total counts bound were detected in either the
matrix or the dish.
To confirm that Sm-C/IGF-I binding to a protein in the
43,000-mol wt complex accounted for the lack of insulin dis-
placement, quiescent fibroblast monolayers were suspended by
trypsinization and incubated with '25I-Sm-C/IGF-I for 4 h at
8°C in the presence and absence of unlabeled Sm-C/IGF-I or
insulin and cross-linked and the proteins were separated by SDS-
Figure 4. Autoradiogram of '25I-Sm-C/IGF-I cross-linked to fibroblast
monolayers and separated on 3-14% gradient SDS-PAGE after reduc-
tion with 100 mM DTT. Lane A: without competing unlabeled pep-
tides, showing predominant binding of 251I-Sm-C/IGF-I to the
1 35,000-mol wt alpha-subunit of type I Sm-C/IGF receptor and the
43,000-mol wt cell-associated, 251I-Sm-C/IGF-I binding protein com-
plex. Lane B. competition with unlabeled Sm-C/IGF-I 50 ng/ml.
Lanes C and D: competition with insulin, 0.5 and 20 jg/ml, respec-
tively, showing a significant reduction in '25I-Sm-C/IGF-I binding to
the 135,000-mol wt alpha-subunit of type I receptor without reduction
in binding in the 43,000-mol wt complex. Lane E: competition with
10-' M alpha-IR3, showing selective competition of '`'I-Sm-C/IGF-I
binding to the alpha-subunit of type I receptor and apparent increase
in '25I-Sm-C/IGF-I binding in the 43,000-mol wt complex.
PAGE. In contrast to the monolayers no binding to the 43,000-
mol wt protein was present and the 1251-Sm-C/IGF-I was bound
only to the 135,000-mol wt type I receptor (Fig. 6). The bound
'25I-Sm-C/IGF-I could be displaced with either unlabeled Sm-
C/IGF-I, insulin, or alpha-IR3. Similar results were obtained if
the cells were mechanically removed from the plate and not
exposed to trypsin.
To determine whether this binding protein in the 43,000-
mol wt complex could be secreted by the fibroblast monolayers
into the culture medium, conditioned medium from the fibro-
blast monolayers was incubated with '25I-Sm-C/IGF-I and re-
acted with DSS. After separation by PAGE, the '251-Sm-C/IGF-
I was cross-linked to three fibroblast media proteins. The mo-
lecular weights ofthe complexes were 43,000, 36,000 and 25,000
(Fig. 7). The 43,000- and 36,000-mol wt bands were less intensely
labeled after addition of unlabeled Sm-C/IGF-I and IGF-II, but
not after addition of insulin. In contrast, when conditioned me-
dium was collected for 72 h from suspension cultures and cross-
linked to 1251 Sm-C/IGF-I, no 43,000-mol wt binding moiety
was detectable (data not shown).
To determine the functional significance of this 43,000-mol
wt protein complex, conditioned medium from quiescent fibro-
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Figure S. Autoradiogram of '25I-Sm-C/IGF-I cross-linked to fibroblast
monolayers and separated on 3-14% gradient SDS-PAGE after reduc-
tion with 100 mM DTT. Lane A: without competing unlabeled pep-
tides. Lanes B-F: with increasing concentrations of unlabeled Sm-C/
IGF-I, from 0.1 to 1O ng/ml, showing an increase in '251-Sm-C/IGF-I
labeling of both 1 35,000-mol wt alpha-subunit and the 43,000-mol wt
complex.
blast cultures obtained after 72 h of incubation was tested for
its effects on the binding of '251I-Sm-C/IGF-I to porcine aortic
smooth muscle cells (a cell type that does not secrete a binding
moiety capable of associating with the cell surface). We have
shown that quiescent porcine aortic smooth muscle cell mono-
layers possess type I receptors and that the '251I-Sm-C/IGF-I that
binds to this receptor is displaceable by unlabeled Sm-C/IGF-I
and insulin. After 24 h ofexposure to either fibroblast or smooth
muscle cell-conditioned medium, '251I-Sm-C/IGF-I binding was
determined. Control monolayers exposed to smooth muscle cell-
conditioned medium showed displacement of '251I-Sm-C/IGF-I
at low concentrations of unlabeled Sm-C/IGF-I (1-5 ng/ml),
and concentrations of unlabeled insulin between 1 and 10 jsg/
ml also caused significant displacement (Fig. 8). In contrast,
cultures that were preincubated with fibroblast-conditioned me-
dium showed a 60% increase in basal '251-Sm-C/IGF-I binding
that further increased when increasing concentrations of unla-
beled Sm-C/IGF-I were added. Addition of unlabeled Sm-C/
IGF-I in concentrations as high as 25 ng/ml were required to
obtain any displacement, and insulin in concentrations as high
as 1.0 mg/ml caused no displacement. To determine that this
was not a property of one fibroblast line, conditioned media
were obtained from eight different fibroblast strains and prein-
cubated with smooth muscle cell monolayers. Media from all
eight strains were shown to increase basal '251-Sm-C/IGF-I bind-
ing and to change the relative sensitivity to competition by un-
labeled Sm-C/IGF-I (data not shown). Exposure of smooth
muscle cell cultures to conditioned media obtained from fibro-
blast suspension cultures for 24 h did not result in changes in
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Figure 6. Autoradiogram of 125I-Sm-C/IGF-I crosslinked to fibroblasts
in suspension and separated on 3-14% gradient SDS-PAGE after re-
duction with 100 mM DTT. Lane A: without competing unlabeled
peptides, showing '25I-Sm-C/IGF-I binding predominantly to 135,000-
mol wt alpha-subunit of type I receptor, with little or no binding asso-
ciated with the 43,000-mol wt complex. Lanes B-F: competition with
increasing concentrations of unlabeled Sm-C/IGF-I. Lane G: competi-
tion with insulin, 1 ug/ml.
in fibroblast monolayer-conditioned media could alter Sm-C
binding to suspended fibroblasts, 120,000 cells/tube were exposed
to a 20% (vol/vol) concentration of fibroblast monolayer-con-
ditioned medium (that had been concentrated fivefold) for 14
h at 370C. After addition of increasing concentrations of unla-
beled Sm-C (1-10 ng/ml) 1251-Sm-C binding increased -56%
above basal at 4 ng/ml then decreased toward control levels.
To confirm that the effect of fibroblast-conditioned medium
on 1251-Sm-C binding to smooth muscle cells was associated with
attachment of a protein represented in the 43,000-mol wt 1251.
Sm-C/IGF-I-protein complex, cross-linking studies were per-
formed using smooth muscle cells that had been exposed to
fibroblast-conditioned medium. After exposure to this medium
and cross-linking, '251-Sm-C/IGF-I was associated with three
proteins in the smooth muscle cell monolayers (Fig. 9): a
1 35,000-mol wt band that was lessened in intensity in the pres-
ence of insulin and obliterated by unlabeled Sm-C/IGF-I, a
43,000-mol wt band that could not be displaced with unlabeled
insulin, and a 260,000-mol wt band. In contrast, control cultures
that had been exposed to smooth muscle cell-conditioned media
showed intense '25I-Sm-C/IGF-I labeling in the 135,000-mol wt
band, as well as less intense labeling at 260,000. Both bands
were displaced with increasing unlabeled Sm-C/IGF-I or insulin.
Ofinterest was the observation that cross-linking ofradiolabeled
Sm-C/IGF-I to smooth muscle cell-conditioned media showed
that a 35,000-mol wt protein that bound radiolabeled Sm-C was
present.
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Figure 7. Autoradiogram of '251I-Sm-C/IGF-I cross-linked to proteins
in the conditioned medium from fibroblast monolayers (prepared as
described in the text) and separated on 10% SDS-PAGE after reduc-
tion with 10 mM BME. Lane A: without competing unlabeled pep-
tides. Lanes B and C: competition with Sm-C/IGF-I, 20 and 50 ng/ml,
respectively, showing significant competition by 50 ng/ml of unlabeled
peptide for '23-Sm-C/IGF-I binding associated with the 43,000- and
36,000-mol wt complexes and less significantly with the 25,000-mol
wt complex. Lanes D and E: competition with unlabeled IGF-II, 50
and 200 ng/ml, which shows a competition by 200 ng/ml of this unla-
beled peptide equivalent to unlabeled Sm-C/IGF-I, at 50 ng/ml (lane
C). Lane F: competition with unlabeled insulin, 10 g/ml, showing no
competition to '2I-SmC/IGF-I binding associated with the 43,000-,
36,000-, and 25,000-mol wt complexes.
Preliminary physicochemical properties of the factor in the
43,000-mol wt '251-Sm-C/IGF-I protein complex are: (a) it is
retained by dialysis using 3,500-mol wt exclusion membrane,
destroyed by proteases, (b) it is heat stable at 560C for 2 h but
partially inactivated by heating to 800C for 1 h, and (c) it is
stable at pH 2.5 and 10.6 (Table II).
Discussion
These findings demonstrate that cultured human fibroblast
monolayers secrete a 35,000-mol wt protein (43,000 minus
7,600, the molecular weight of '25I-Sm-C/IGF-I) into culture
medium. This protein is capable of binding Sm-C/IGF-I and
alters Sm-C/IGF-I binding to fibroblast monolayers. Further-
more, our affinity-labeling and competition studies suggest that
it is the major binding species detectable after cross-linking to
confluent monolayers. The protein has the characteristics of a
Sm-C/IGF-I-binding protein because it is secreted by cultured
cells into the media, binds Sm-C/IGF-I avidly, and does not
bind insulin. The property that appears to distinguish it from
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Figure 8. Binding of '25I-Sm-C/IGF-I to smooth muscle cell monolay-
ers after exposure to fibroblast conditioned medium. Smooth muscle
cell monolayers (92,000 cells/well) were exposed to fibroblast (o) or
smooth muscle cell (.)-conditioned medium for 24 h at 370C. After
incubation the cultures were washed extensively, and '251I-Sm-C/IGF-I
(80,000 cpm/well) was added. Increasing concentrations of unlabeled
Sm-C/IGF-I (left) and insulin (right) were added to triplicate cultures.
Cell-associated radioactivity was determined as in Fig. 1.
it appears to associate with cellular membranes ofboth fibroblasts
and smooth muscle cells. The latter characteristic is not common
to all fibroblast-secreted Sm-C/IGF-I-binding proteins, because
we found no evidence of an association of the fibroblast media
36,000- and 25,000-mol wt '25I-Sm-C/IGF-I-binding protein
complexes with either fibroblast or smooth muscle cell lysates.
It is possible that these binding proteins are not unique species
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Figure 9. Autoradiogram of '25I-Sm-C/IGF-I cross-linked to porcine
smooth muscle cell monolayers and separated on 3-14% gradient
SDS-PAGE after reduction with 100 mM DTT. Lanes A-C: incuba-
tion was performed in conditioned medium from pig smooth muscle
cells. Lanes D-F: incubation was performed in conditioned medium
from fibroblasts. Lanes A and D: without competing unlabeled pep-
tides. Lanes B and E: competition with 50 ng/ml Sm-C/IGF-I. Lanes
C and F: competition with unlabeled insulin, I Ag/ml.
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Table II. Effect ofHeat, pH, and Proteolysis on






560C 2 h 183
800C I h 99
-20'C 1 wk 186
-700C 1 wk 177
Protease treatment 2 h 370C 94
Conditioned media was collected from fibroblast monolayers after a
72-h incubation. It was concentrated 33-fold by lyophilization then
exposed to the perturbation listed. Acidification and base exposure
were conducted for 30 min at room temperature. The protease prepa-
ration was a mixture of proteolytic enzymes obtained from Strepto-
myces griseus linked to agarose purchased from Sigma Chemical Co.
It was used at a final concentration of 0.04 U/ml.
but represent proteolytic cleavage products ofthe binding moiety
in the 43,000-mol wt complex that have retained the capacity
to bind Sm-C/IGF-I but not to the cell surface. Whether or not
this is the case the binding protein in the 43,000-mol wt moiety
appears to be unique because it can associate with the cell surface.
Furthermore, after exposure to this protein competition of un-
labeled Sm-C/IGF-I or insulin for '25I-Sm-C/IGF-I binding to
smooth muscle cells is greatly altered, suggesting that the 35,000-
mol wt protein may directly alter binding to the type I receptor.
The conclusion that the 35,000-mol wt protein accounts for
the differences observed in radiolabeled Sm-C/IGF-I binding
between fibroblast monolayers and suspensions is supported by
several observations. First, it is associated with the cell lysates
of fibroblast monolayers but not the same cells in suspension,
suggesting that it is responsible for the differences in displacement
of 1251I-Sm-C/IGF-I between these conditions. Second, because
the 35,000-mol wt protein does not bind insulin its presence on
monolayers may account for the inability of insulin2 to displace
labeled Sm-C/IGF-I from monolayers (but not from suspension
cultures). Similarly, because antibody to the type I receptor (al-
pha-IR3) does not recognize the 35,000-mol wt protein, this
explains the lack of capacity of alpha-IR3 to displace labeled
Sm-C/IGF-I from the monolayers. Third, the suspended fibro-
blasts do not appear to secrete this protein. Taken together with
our finding that media containing the 35,000-mol wt protein
can alter the binding characteristics of smooth muscle cultures
in a similar fashion, our data support the concept that the 35,000-
mol wt protein directly alters Sm-C/IGF-I cellular binding.
Our data do not provide a definitive explanation of the par-
adoxical increase in '25I-Sm-C/IGF-I binding that occurs when
2. It is also possible that some '251-IGF-I/Sm-C is bound to type II re-
ceptors and, therefore, cannot be displaced with insulin. A 260,000-mol
wt band was detected after cross-linking but insulin and alpha-IR3 could
compete with 25I-IGF-I/Sm-C for binding to this protein, suggesting
that it is a dimer of the alpha-subunit of the type I receptor and not the
type II receptor. Nevertheless, it is possible that the type II receptor was
not efficiently extracted with SDS and is present in greater concentration
than our extraction method would indicate.
low concentrations of unlabeled Sm-C/IGF-I are added to these
cultures. Gel electrophoresis data confirm that significant dis-
placement of labeled Sm-C/IGF-I from either the 35,000-mol
wt protein or the 135,000-mol wt type I receptor does not occur
at concentrations ofunlabeled Sm-C/IGF-I below 20 ng/ml and
suggest that binding to these proteins is increasing at concen-
trations between I and 10 ng/ml. Two explanations for these
results seem possible. First, when unlabeled Sm-C/IGF-I is added
there could be a direct increase in the affinity (positive cooper-
ativity) ofeither the 35,000-mol wt protein or the type I receptor
or both that could result in increasing the binding of 125I-Sm-
C/IGF-I. Second, it is possible that when low concentrations of
unlabeled peptide are added it displaces radiolabeled Sm-C/IGF-
I from binding proteins in the media and makes '251I-Sm-C/IGF-
I more available to bind the cell surface receptor. This hypothesis
is unlikely because radiolabeled peptide is present in excess under
the experimental conditions. Furthermore, the smooth muscle
cell media contains a protein that forms a 43,000-mol wt complex
with 1251I-Sm-C after cross-linking yet no paradoxical increase in
'25I-Sm-C binding to the type I receptor appears to occur in
these cells.
Affinity cross-linking studies indicate that the 35,000-mol
wt protein is an important binding moiety associated with human
fibroblast membranes obtained from monolayer cultures. Be-
cause the 35,000-mol wt protein appears to be a specific binding
component of monolayer cultures and is not present in suspen-
sion cultures, it is possible that this protein is associated with
the basement membrane of the monolayers. However, direct
binding studies to basement membranes after cell removal
showed very low levels of binding and after cross-linking to this
material no 43,000-mol wt complex was detected. Furthermore,
the 43,000-mol wt complex can be detected on the suspended
cell surfaces if these cells are exposed to concentrated monolayer-
conditioned media prior to the addition ofcross-linking reagents.
These data support the conclusion that the 43,000-mol wt com-
plex is cell surface-associated.
The presence of this protein adds a third complex variable
to understanding the binding of Sm-C/IGF-I to this cell type.
Knauer and Cunningham (21) have reported that human fibro-
blasts secrete a protein that binds covalently to epidermal growth
factor (EGF) binding protein (termed a protease nexin) and
functions to enhance EGF binding to cultured fibroblast mono-
layers. Although the 35,000-mol wt protein reported here does
not bind Sm-C/IGF-I covalently, it may function in a similar
manner. This or a very similar protein may have previously
been observed during preparation of membrane fractions from
tissues. Grizzard et al. (22) noted a 45,000-mol wt 125_-Sm-C/
IGF-I-binding protein complex in preparations of placental
membrane preparations from preterm placentas. Likewise,
Armstrong et al. (23) used placental membranes and noted a
band between 40,000 and 45,000 that cross-linked with labeled
basic somatomedin. Although in the former study amniotic fluid
was thought to be the source of the protein, it is notable that it
was not completely removed by washing. Because fibroblasts are
present in these tissues it is possible that these authors were
cross-linking to a protein related to the one described herein.
Finally, multiple studies report somatomedin-binding proteins
of similar size in amniotic fluid, serum, and culture media (11,
18, 23).
Other investigators have prepared human fibroblast mem-
branes from suspension cultures for cross-linking studies and
have not reported this protein (7). Because they detached the
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cells from the monolayer it is possible that the 35,000 protein
was removed, or alternately, as shown by Grizzard et al. (22), it
might not have been detected because 5% polyacrylamide gels
were used. Our data support the hypothesis that removal of the
cells from the plate results in a lower cellular affinity for the
35,000-mol wt protein because exposure of suspended cells to
concentrated conditioned media prior to binding studies results
in reinstitution of the paradoxical increase in '25I-Sm-C/IGF-I
binding. Inasmuch as the suspended cells do not secrete the
35,000-mol wt binding protein its continued synthesis and se-
cretion during the binding experiment may be required for it to
be detected. In contrast, when affinity cross-linking studies have
been performed by other investigators directly on fibroblast
monolayers not only is the type I receptor present but a lower
molecular weight IGF-I complex (43,000) is also present (5).
Taken together, these findings suggest that this binding moiety
may be important in modifying the binding, and possibly the
biologic action of Sm-C/IGF-I in many types of proliferating
cells.
These findings are difficult to reconcile with published reports
of Rosenfeld and Dollar (9). They have reported that unlabeled
Sm-C/IGF-I displaces significant quantities of labeled peptide
from newborn foreskin fibroblast monolayers when added in
concentrations of 1-10 ng/ml. In their hands addition ofinsulin
at 8.0 Ag/ml results in a 60% displacement ofbound '251-Sm-C/
IGF-I from monolayer cultures, and their results are consistent
with the existence of only one class of receptors. Differences
between our studies and theirs cannot be attributable to tissue
source, donor age, feeding schedule, or preincubation periods,
as each were similar or identical. Because these authors did not
detail the plating densities utilized nor the purity ofthe peptides
employed, it remains possible that those differences account for
the discrepancies noted for Sm-C/IGF-I displacement. The dis-
crepancies in the findings of insulin displacement remain un-
resolved.
These findings indicate that fibroblasts secrete a protein that
functions not only to alter Sm-C/IGF-I binding to human fi-
broblast receptors but also has the potential for altering cellular
response to this peptide. Our laboratory has previously described
the secretion of a somatomedinlike factor by fibroblasts that
augments the cellular response to exogenously added Sm-C/IGF-
1 (24). Therefore, it is possible that the 35,000-mol wt protein
represents a closely related factor. Fibroblast DNA synthesis can
be stimulated by very low concentrations of Sm-C/IGF-I (e.g.,
1-10 ng/ml). This finding indicates that the 35,000-mol wt pro-
tein may not be blocking the response to Sm-C/IGF-I in that
the relatively high concentrations required for competition in
these studies (e.g., 25-300 ng/ml) are not required for replication.
It is possible that this factor actually enhances the cellular re-
sponsiveness to exogenously added Sm-C/IGF-I. Secretion of
this factor could represent an important signal molecule in cell-
cell interaction between fibroblasts or between fibroblasts and
smooth muscle cells. In this regard there is evidence that after
injury to vessel walls fibroblasts may suppress smooth muscle
cell division and proliferate in areas where smooth muscle cells
previously have dominated (25). Further studies will be required
to analyze the effect of this peptide on smooth muscle cell di-
vision.
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